Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.61 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626194 | 0.92 | CCR1 (0.58) | CCR1CXCR3HTTLMNAALDH1A1 | |
| SCHEMBL1638723 | 0.91 | CCR1 (0.67) | CCR1CXCR3HTTLMNAALDH1A1 | |
| SCHEMBL12624493 | 0.87 | CCR1 (0.74) | CCR1ALDH1A1MAPT | |
| SCHEMBL1637827 | 0.86 | CCR1 (0.77) | CCR1TP53 | |
| SCHEMBL10063572 | 0.83 | CCR1 (0.66) | CCR1CXCR3HTTLMNAALDH1A1 | |
| SCHEMBL1637373 | 0.83 | CCR1 (0.64) | CCR1CXCR3LMNAALDH1A1MAPT | |
| SCHEMBL13355955 | 0.82 | CCR1 (0.65) | CCR1CXCR3LMNAALDH1A1MAPT | |
| SCHEMBL13456282 | 0.82 | CCR1 (0.56) | CCR1CXCR3 | |
| SCHEMBL1638044 | 0.81 | CCR1 (0.87) | CCR1 | |
| SCHEMBL10080244 | 0.80 | CCR1 (0.83) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | SOST, VDR, PTH1R | CCR1 1499/4885CXCR3 314/4885HTT 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.